Abbott Laboratories $ABT Shares Bought by Czech National Bank

Key Points

• The Czech National Bank increased its holdings in Abbott Laboratories by 6.8%, acquiring an additional 26,900 shares during the second quarter, bringing its total to 425,277 shares worth approximately $57.84 million.
• Abbott Laboratories reported earnings of $1.26 EPS for the recent quarter, matching analyst expectations, with revenues increasing by 7.4% year-over-year to $11.14 billion.
• Following a recent share sale by CFO Philip P. Boudreau, institutional investors now own 75.18% of Abbott Laboratories, while internal stakeholders hold only 0.46% of the stock.

Czech National Bank lifted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 6.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 425,277 shares of the healthcare product maker's stock after purchasing an additional 26,900 shares during the period. Czech National Bank's holdings in Abbott Laboratories were worth $57,842,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ABT. Nuveen LLC purchased a new position in Abbott Laboratories in the first quarter worth approximately $1,658,180,000. GAMMA Investing LLC lifted its stake in Abbott Laboratories by 15,420.4% in the first quarter. GAMMA Investing LLC now owns 5,102,648 shares of the healthcare product maker's stock worth $676,866,000 after acquiring an additional 5,069,771 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Abbott Laboratories by 29.2% in the first quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker's stock worth $2,120,516,000 after acquiring an additional 3,616,471 shares during the last quarter. Wellington Management Group LLP lifted its stake in Abbott Laboratories by 12.8% in the first quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker's stock worth $3,948,117,000 after acquiring an additional 3,371,113 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Abbott Laboratories by 12.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 14,451,305 shares of the healthcare product maker's stock worth $1,916,966,000 after acquiring an additional 1,639,954 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

ABT stock traded up $1.14 on Wednesday, hitting $133.90. The company's stock had a trading volume of 5,113,287 shares, compared to its average volume of 4,659,553. The firm has a 50 day moving average of $130.36 and a two-hundred day moving average of $131.24. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The stock has a market cap of $233.05 billion, a price-to-earnings ratio of 16.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. Abbott Laboratories's revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent research reports. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 price target for the company. Royal Bank Of Canada boosted their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $144.47.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.